




RealRate

# PHARMACEUTICAL 2019

CorMedix Inc.  
Rank 306 of 363





RealRate

# PHARMACEUTICAL 2019

CorMedix Inc.  
Rank 306 of 363



The relative strengths and weaknesses of CorMedix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CorMedix Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 14% points. The greatest weakness of CorMedix Inc. is the variable Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is -112%, being 149% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	18,665
Cost of Goods Sold	397
Intangible Assets	0
Liabilities, Current	7,766
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-1.9
Other Expenses	0
Other Liabilities	6,125
Other Net Income	35
Other Revenues	430
Property and Equipment	161
Research and Development	18,822
Selling, General and Administrative Expense	8,075

Output Variable	Value in 1000 USD
Assets	18,826
Liabilities	13,892
Expenses	27,294
Revenues	430
Stockholders Equity	4,934
Net Income	-26,830
Comprehensive Net Income	-26,831
Economic Capital Ratio	-112%